[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"leadSponsorName\":\"Moleac Pte Ltd.\",\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:":84},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,2,0,[8,49],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":15,"eligibilityCriteria":16,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":19,"targetDuration":4,"studyType":22,"phases":23,"briefSummary":25,"conditions":26,"keywords":28,"overallStatus":36,"whyStopped":4,"lastUpdateSubmitDate":37,"lastUpdatePostDateStruct":38,"startDateStruct":41,"completionDateStruct":43,"leadSponsor":45,"locationsCount":48},"100607628","phase-3-alzheimers-disease-therapy-with-neuroaid-ii-100607628",false,"NCT07191028","Alzheimer's Disease THErapy With NEuroaid II","A Multicenter, Randomized, Double-blind, Placebo-controlled, Parellel-group Study to Assess the Efficacy and Safety of MLC901 (NeuroAiD™II) in Subjects With Mild to Moderate Alzheimer's Disease (AD).","ATHENE II","Inclusion Criteria:\n\n* Male or female subjects aged ≥ 50 years at the time of providing informed consent.\n* Diagnosis of AD based on the National Institute on Ageing and the Alzheimer's Association (NIA-AA) criteria, supported by the presence of a Core 1 AD biomarker, specifically elevated plasma ptau217 ≥0.471 pg\u002FmL.\n* MMSE score between 10 and 26, inclusive, at baseline, corresponding to mild to moderate AD.\n* Subjects may be either treatment-naïve or currently receiving stable symptomatic treatment for AD for at least the 2 months prior to screening, including AChEIs, memantine, or a combination of both.\n* Subjects must have a designated study partner who provides ongoing support during the study and interacts with the subject for a minimum of 8 hours per week, and will accompany the subject to study visits or be available by telephone at designated times.\n\nA second study partner may serve as backup. If the original study partner withdraws from participation, a replacement study partner may be permitted at the investigator's discretion. The replacement study partner must provide informed consent prior to their first study visit with the subject.\n\n* Both the subject (or their legally authorized representative) and the study partner(s) must be capable of providing informed consent.\n* Subjects must have adequate literacy, vision, and hearing, in the opinion of the investigator at the time of screening, to allow for valid administration of the clinical outcome assessments.\n\nExclusion Criteria:\n\n* Presence of any neurological disorder contributing to cognitive impairment other than AD, including but not limited to: Parkinson's disease, Dementia with Lewy bodies, and epilepsy or recurrent seizures.\n* Evidence of other clinically significant cerebrovascular disease or intracranial abnormalities based on the latest brain CT or MRI, including but not limited to: multiple lacunar infarcts, large territorial infarcts, severe small vessel or white matter disease, normal pressure hydrocephalus, space occupying lesions.\n\nThe most recent available scan (obtained at diagnosis or subsequently) is usually sufficient for screening eligibility to exclude these other conditions. Repeat imaging may need in some cases to be considered if there is clinically significant deterioration or new neurological signs suggestive of a cerebrovascular event.\n\n* Presence of any serious or unstable medical illnesses, including but not limited to: cardiovascular, respiratory, gastroenterological, endocrinologic, immunologic, hematologic, hepatic, or renal and other conditions, that, in the investigator's judgment, may interfere with study participation or compromise subject safety.\n* Patients with a CDR Global Score of 0, 0.5 or 3 at the Screening Phase, corresponding to no, very mild or severe dementia, respectively, will be excluded from the study.\n* Severe visual or hearing impairment that would prevent the subject from accurately completing clinical outcome assessments.\n* Serum creatinine \\> 130 µmol\u002FL at baseline, which may affect plasma biomarker analysis.\n* Female subjects who are pregnant at screening.\n* Participation in another clinical trial or receipt of any investigational product within 60 days or 5 half-lives (whichever is longer) prior to screening.\n* Current use at baseline of any AD disease modifying therapies including anti-amyloid therapy or neuroprotective\u002Fnootropic agents, including Ginkgo biloba, Neurotain, Citicoline, Cerebrolysin, or Piracetam.\n* Known hypersensitivity or allergic reaction to MLC901 or any of its components. Any known food allergy or hypersensitivity to Astragalus membranaceus, Ligusticum chuanxiong, Polygala tenuifolia, Angelica sinensis or members of the Fabaceae\u002FLeguminosae family (e.g., legume, pea, bean), Polygalaceae family (e.g., milkwort, snakeroot), Apiaceae\u002FUmbelliferae family (e.g., anise, caraway, carrot, celery, dill, parsley, parsnip) or Quillaja bark (soapbark).","ALL","50 Years",{"count":20,"type":21},350,"ESTIMATED","INTERVENTIONAL",[24],"PHASE3","ATHENE II is a multicenter, randomized, double-blind, placebo-controlled, parallel-group trial designed to evaluate the efficacy and safety of MLC901 in subjects with mild to moderate Alzheimer's disease, as well as its effects on plasma biomarkers compared to placebo.",[27],"Alzheimer's Disease Dementia",[29,30,31,32,33,34,35],"MLC901","NeuroAiD™II","Alzheimer's disease","multicenter","randomised","double blind","placebo controlled","NOT_YET_RECRUITING","2026-06-10",{"date":39,"type":40},"2026-06-12","ACTUAL",{"date":42,"type":21},"2026-08",{"date":44,"type":21},"2029-05",{"name":46,"class":47},"Moleac Pte Ltd.","INDUSTRY",1,{"id":50,"slug":51,"hasResults":11,"nctId":52,"briefTitle":53,"officialTitle":54,"acronym":55,"eligibilityCriteria":56,"healthyVolunteers":11,"sex":17,"minAge":57,"maxAge":4,"enrollmentInfo":58,"targetDuration":4,"studyType":22,"phases":60,"briefSummary":62,"conditions":63,"keywords":71,"overallStatus":36,"whyStopped":4,"lastUpdateSubmitDate":76,"lastUpdatePostDateStruct":77,"startDateStruct":79,"completionDateStruct":81,"leadSponsor":83,"locationsCount":4},"100442801","phase-2-mlc1501-study-assessing-efficacy-in-stroke-recovery-100442801","NCT05046106","MLC1501 Study Assessing Efficacy in STROke Recovery","A Randomized, Double-Blind, Placebo-Controlled, Dose-Response Efficacy and Safety Study of MLC1501 in Patients With Stroke","MAEStro","Inclusion Criteria:\n\n* Male or female.\n* 18 years old or older.\n* Diagnosed with acute ischemic stroke with compatible brain imaging findings between 2 days to 7 days prior to inclusion. Patients who undergo intravenous or endovascular thrombolysis or thrombectomy must be considered stable for at least 24 hours post-procedure prior to inclusion.\n* NIHSS total score of 8 to 18 (inclusive) at the time of inclusion with a combined score of at least 2 on the NIHSS motor items 5A or 5B and\u002For 6A or 6B.\n* A candidate for active rehabilitation in the opinion of the treating physician.\n* Able to comply with the requirements of the protocol and provide written informed consent by patient or legal representative before any study-specific procedure is performed.\n\nExclusion Criteria:\n\n* Pre-stroke modified Rankin score of \\>1.\n* Contraindication to any of the study procedures.\n* Participation in another investigational drug or device trial within the past 30 days.\n* Intake of warfarin in the past one week or expected to be on warfarin while in the study.\n* Women who are pregnant, breastfeeding, of child-bearing potential or planning to become pregnant during the study. Menopausal\u002Fpost-menopausal women without menstruation for 12 consecutive months or surgically sterilized women may be included. Intake of oral contraceptive pills or hormone replacement therapy is not allowed. Use of mechanical barriers, e.g., condom, intrauterine device, are allowed. Local contraception requirements for clinical trials should be followed.\n* Any known food allergy or hypersensitivity to Astragalus membranaceus, Ligusticum chuanxiong, Polygala tenuifolia, Angelica sinensis, or members of the Fabaceae\u002FLeguminosae family (e.g., legume, pea, bean), Polygalaceae family (e.g., milkwort, snakeroot), Apiaceae\u002FUmbelliferae family (e.g., anise, caraway, carrot, celery, dill, parsley, parsnip), or Quillaja bark (soapbark).\n* Evidence of other significant non-ischemic brain lesion which could affect long-term function or disability.\n* Evidence of advanced medical condition that would affect study assessment and follow-up, such as cancer, renal failure, liver cirrhosis, severe dementia, or psychosis.\n* Any other medical or psychiatric or cognitive condition which, in the study investigator's opinion, may jeopardize the patient by his\u002Fher participation in this study, may hamper his\u002Fher ability to complete procedures required in the study, affect study assessment and follow-up, or affect the validity of the study results","18 Years",{"count":59,"type":21},540,[61,24],"PHASE2","This is a multi-center, randomized, double-blind, placebo-controlled, dose-response study of MLC1501 in patients with stroke. Eligible participants will be randomized in a 1:1:1 ratio to orally receive MLC1501 low-dose twice a day, MLC1501 high-dose twice a day, or matching placebo for 24 weeks.",[64,65,66,67,68,69,70],"Stroke","Stroke, Ischemic","Strokes Thrombotic","Stroke Sequelae","Stroke, Cardiovascular","Stroke, Embolic","Stroke, Cryptogenic",[72,73,55,74,75],"stroke","MLC1501","stroke recovery","neurorestoration","2023-03-14",{"date":78,"type":40},"2023-03-16",{"date":80,"type":21},"2025-01",{"date":82,"type":21},"2028-12",{"name":46,"class":47},""]